PhI/II DosEscalDosExpan&CohortExpanFMC376 Particip w/KRASG12C MutatLocalAdvUnresec orMetsSolidTuFarshid DayyaniOPEN TO ACCRUALGet More Information
PhIMeninInhibitorSNDX-5613ComboW/Daunorubicin&CytarabineNewDxPtsW/AcuteMyeloidLeukemia&NPM1Kiran NaqviOPEN TO ACCRUALGet More Information
PhII Study Amivantamab EGFR or MET- Amplified Esophagogastric CaFarshid DayyaniOPEN TO ACCRUALGet More Information
PhII EvalEfficSaf&Impact TuMicroen CombTocilizumabAtezolizumab&FractioStereotac Radiothe Recur GliobXiao-Tang KongOPEN TO ACCRUALGet More Information
PhIITriapine+Lutetium177DotatatVsLutetium177DotatAloneWellDifferentiatSomatostatinRecept+NeuroendoTuFarshid DayyaniOPEN TO ACCRUALGet More Information
Lutikizumab for Therapy in Subjects with Moderately to Severely Active Ulcerative ColitisSandra ParkOPEN TO ACCRUALGet More Information
ParalPhIIIRandTriGenomicRiskStratifiedUnfavInterRisProstaCaDeIntensific&IntensificClinTriEvaluGUIDANDavid HongOPEN TO ACCRUALGet More Information
PhIbDosEscaPhIIDosOptOralZongertinibCombw/IntravenT-DXdCombw/IntraT-DM1 TxPaw/AdvHER2+mBC&mGEACFarshid DayyaniOPEN TO ACCRUALGet More Information
Efficacy & Safety of CG-100 Intraluminal Bypass Device in Colorectal & Coloanal AnastomosesJoseph CarmichaelOPEN TO ACCRUALGet More Information
RandomPhIIStudy CabozantinibIpilimumab&Nivolumab Pa w/SoftTissue SarcomaWarren A ChowOPEN TO ACCRUALGet More Information
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females with Obstetric Injury (DignJoseph CarmichaelOPEN TO ACCRUALGet More Information
ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with CKD from CSA-AKI and MAKE Jack SunOPEN TO ACCRUALGet More Information
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People with ALSNamita GoyalOPEN TO ACCRUALGet More Information
JanusRectalCancerTrial: PhII TripletVSDoublet ChemoClinicalComplete Response Pa w/LocallyAdvRectalCaJason ZellOPEN TO ACCRUALGet More Information
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS or PMSMichael SyOPEN TO ACCRUALGet More Information
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific ChimerPriyanka IyerOPEN TO ACCRUALGet More Information
Evaluate Safety of a Single Intravitreal Injection of RTx-015 in Patients with Retinitis PigmentosaBaruch KuppermannOPEN TO ACCRUALGet More Information